Evolent Health (NYSE:EVH) and SOPHiA GENETICS (NASDAQ:SOPH) Head-To-Head Review

Evolent Health (NYSE:EVH – Get Free Report) and SOPHiA GENETICS (NASDAQ:SOPH – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Insider and Institutional Ownership

31.6% of SOPHiA GENETICS shares are held by institutional investors. 1.5% of Evolent Health shares are held by insiders. Comparatively, 4.9% of SOPHiA GENETICS shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Evolent Health and SOPHiA GENETICS”s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Evolent Health $1.88 billion 0.29 -$534.51 million ($4.54) -1.08
SOPHiA GENETICS $90.97 million 7.57 -$79.00 million ($1.09) -7.53

SOPHiA GENETICS has lower revenue, but higher earnings than Evolent Health. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Evolent Health, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Evolent Health and SOPHiA GENETICS’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Evolent Health -21.67% -6.07% -1.23%
SOPHiA GENETICS -89.18% -128.69% -44.73%

Volatility and Risk

Evolent Health has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, SOPHiA GENETICS has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Evolent Health and SOPHiA GENETICS, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Evolent Health 1 3 10 0 2.64
SOPHiA GENETICS 1 1 3 0 2.40

Evolent Health presently has a consensus price target of $6.04, indicating a potential upside of 23.61%. SOPHiA GENETICS has a consensus price target of $10.00, indicating a potential upside of 21.80%. Given Evolent Health’s stronger consensus rating and higher possible upside, analysts plainly believe Evolent Health is more favorable than SOPHiA GENETICS.

Summary

Evolent Health beats SOPHiA GENETICS on 8 of the 14 factors compared between the two stocks.

About Evolent Health

(Get Free Report)

Evolent Health, Inc. provides technology-enabled services to health plans and healthcare providers in the United States. The company helps clients manage care, coordinate services and support the delivery of healthcare, particularly for people with complex medical needs. Its offerings include specialty care management programs, clinical and administrative services, and technology that supports care decisions and operations. Evolent has focused on areas such as oncology, cardiology, musculoskeletal care and behavioral health.

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS is a healthcare technology company that develops data-analysis tools for genomics and other complex health data. Its cloud-based SOPHiA DDM platform uses artificial intelligence and analytics to help healthcare and research organizations interpret data and support clinical and scientific decision-making. The platform and related applications are used in areas including oncology, rare diseases and inherited conditions. The company serves hospitals, laboratories, biopharmaceutical companies and research organizations, with a presence across international markets.

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.